Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3)
This study is currently recruiting participants.
Verified July 2012 by Medical University of South Carolina
Sponsor:
Medical University of South Carolina
Information provided by:
Medical University of South Carolina
ClinicalTrials.gov Identifier:
NCT01139164
First received: June 4, 2010
Last updated: July 24, 2012
Last verified: July 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is study is for patients that have been diagnosed with high-risk hematological malignancies. The main purpose of this study is to confirm previously published results of stem cell transplantation with reduced intensity pre-transplant conditioning. Patients will be assigned to 1 of 3 regimens depending on the patient's diagnosis. Participants will be followed by the transplant team for the remainder of the patient's life. Patient's will visit MUSC daily, then visits will be reduced to frequent visits for up to 6 months. After 6 months, the visits will be reduced more depending on the patient's condition.
| Condition | Intervention |
|---|---|
|
Hematological Malignancies |
Drug: Regimen A Drug: Regimen B Drug: Regimen C |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3) |
Resource links provided by NLM:
Further study details as provided by Medical University of South Carolina:
Primary Outcome Measures:
- To determine the treatment-related mortality rate of allogeneic stem cell transplants using reduced-intensity conditioning regimens within 1st 100-days. [ Time Frame: 8 years ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- To determine the engraftment rate of allogeneic stem cell transplants [ Time Frame: 8 years ] [ Designated as safety issue: Yes ]
To determine the engraftment rate of allogeneic stem cell transplants using reduced-intensity conditioning regimens.
To determine the morbidity, including the pattern and severity of complications, of allogeneic stem cell transplants using reduced-intensity conditioning regimens.
| Estimated Enrollment: | 89 |
| Study Start Date: | June 2010 |
| Estimated Study Completion Date: | June 2018 |
| Estimated Primary Completion Date: | June 2018 (Final data collection date for primary outcome measure) |
Intervention Details:
-
Drug: Regimen A
Chronic Lymphocytic Leukemia/ Chronic Prolymphocytic Leukemia, Multiple Myeloma.
Drug: Regimen B
Other malignancies not addressed in A or C
Drug: Regimen C
B-Cell Lymphomas
Eligibility| Ages Eligible for Study: | 1 Year to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- A proven diagnosis of one of the conditions in Table 1.
- Prior therapy including blood or marrow transplant will not exclude patients for reduced intensity transplant.
- Age < 75 years. Pediatric patients are eligible from the ages of 1 month to 18 years if the transplant physician believes that co-morbid conditions significantly increase the risk for a standard transplant regimen.
- HIV antibody negative.
- ECOG performance status 0-3, (or equivalent Karnofsky and Lansky performance scores for patients <18yrs, see appendix 2)
- Availability of an HLA-identical related donor or suitable alternative donor, (≥7/8 allele match at A, B, C and DRB). Syngeneic transplants will not be allowed in this protocol.
- Due to the complexity of the study, all patients prior to enrollment will be assessed by the PI or co-PI.
- Patient with marrow failure states or immune deficiency syndromes undergoing stem cell transplants must be reviewed by one of the investigators to determine eligibility for study.
- Adequate insurance coverage (or financial resources) to cover the costs associated with the patient's transplant and, in the case of patients eligible for cohort C, to cover the costs associated with I 131 Tositumomab treatment.
Exclusion Criteria:
- Active CNS involvement with malignant disease.
- Pregnancy.
- Fertile men or women unwilling to use contraceptive techniques during the study period.
- Creatinine clearance < 30 ml/min.
- Left ventricular ejection fraction <30% or clinical cardiac failure uncontrolled by medical therapy.
- Pulmonary disease requiring supplemental oxygen therapy.
- Patients with estimated life span less than 1 year due to medical illnesses other than the condition being treated on the study.
Donor Selection:
Inclusion Criteria
- Major HLA identical relative or genotypically matched unrelated donor (7-8/8 alleles) .
- Donors must meet the selection criteria as defined by the Foundation for the Accreditation of Cell Therapy (FACT) and will be screened per the American Association of Blood Banks (AABB) guidelines.
Exclusion Criterion
- Positive anti-donor HLA antibody.
- Identical twin.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01139164
Contacts
| Contact: Jessica Simons | (843) 792-8856 | simonsjl@musc.edu |
| Contact: Amy Johnson, CCRP | (843)792-1789 | johnsae@musc.edu |
Locations
| United States, South Carolina | |
| Medical University of South Carolina | Recruiting |
| Charleston, South Carolina, United States, 29425 | |
| Contact: Karen Rogers 843-792-2740 rogersk@musc.edu | |
| Principal Investigator: Robert Stuart, MD | |
Sponsors and Collaborators
Medical University of South Carolina
Investigators
| Principal Investigator: | Robert Stuart, MD | Medical University of South Carolina |
More Information
No publications provided
| Responsible Party: | Robert Stuart, MD, Medical University of South Carolina |
| ClinicalTrials.gov Identifier: | NCT01139164 History of Changes |
| Other Study ID Numbers: | 101370, HR#19490 |
| Study First Received: | June 4, 2010 |
| Last Updated: | July 24, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Medical University of South Carolina:
|
high-risk hematological malignancies |
Additional relevant MeSH terms:
|
Neoplasms Hematologic Neoplasms Neoplasms by Site Hematologic Diseases |
ClinicalTrials.gov processed this record on May 23, 2013